februar 11, 2020
CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today commenced its previously announced rights offering to raise gross proceeds of $30.0 million (the “Rights Offering”). Under the terms of the...


Ny test kan afsløre farlige modermærker
14. februar 2020
Brainy Days – rejs med ind i hjernen
10. februar 2020
Astma programmeres tidligt i livet
7. februar 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge